US Patent

US8865698 — Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds

Method of Use · Assigned to Array Biopharma Inc · Expires 2029-10-21 · 3y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating various conditions in mammals using a therapeutically effective amount of a compound of Formula I.

USPTO Abstract

Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which R 1 , R 2 , R 3 , R 4 , X, Y and n have the meanings given in the specification.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2469 larotrectinib-sulfate
U-2469 larotrectinib-sulfate
U-2469 larotrectinib-sulfate

Patent Metadata

Patent number
US8865698
Jurisdiction
US
Classification
Method of Use
Expires
2029-10-21
Drug substance claim
No
Drug product claim
No
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.